Corneal Edema | sciencenewsnet.in

Breaking News

Tailbone Pain Awareness Day (Nov. 13): Shedding Light on a Commonly Overlooked Condition

Probing Neutron Star Crusts with Artificial Neural Networks

New Report Examines Barriers to Oral Health Services for New Yorkers

Setting New Research Vision for Cedars-Sinai Guerin Children’s

Is Weight Loss Surgery right for me?

Anti-Inflammatory and Neuroprotective Polyphenols Derived from the European Olive Tree, Olea europaea L., in Long COVID and Other Conditions Involving Cognitive Impairment

Cohesin RAD21 Gene Promoter Methylation in Patients with Acute Myeloid Leukemia

PIM-1L Kinase Binds to and Inactivates SRPK1: A Biochemical and Molecular Dynamics Study

Natural volatiles preventing mosquito biting: an integrated screening platform for accelerated discovery of ORco antagonists

Polymorphic positions 349 and 725 of the autoimmunity-protective allotype 10 of ER aminopeptidase 1 are key in determining its unique enzymatic properties

09 Nov, 2024

Emmecell Completes Last Patient Last Visit for Proof-of-Concept Trial of Groundbreaking Cell Therapy for Corneal Edema

October 8, 2024 sarah JonasResearch Results

Emmetrope Ophthalmics, LLC (“Emmecell”), a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of serious eye diseases, today announced the successful completion of the last patient last visit in its phase 1 extension study EMME-001, a 21-patient randomized, double-masked, US based, multi-center trial assessing the safety and efficacy of EO2002 for the treatment of corneal edema.